Let's see how the company performed during the three months. The post Telix shares rocket 15% on stellar Q1 sales update ...

Telix Pharmaceuticals' quarterly report shows a strong revenue contribution from its acquired nuclear medicine business RLS ...

The first patient was dosed in the Phase 1 ZOLAR 7 trial of TLX300-CDx ( 89 Zr-olaratumab), which aims to validate the use of olaratumab, an antibody exclusively licensed from Eli Lilly and Company ...

Cardinal Health (NYSE:CAH) has been selected as a distributor for Telix Pharmaceuticals' Gozellix®, an important development ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

To support the rollout, Cardinal Health has deployed Telix’s ARTMS QUANTM Irradiation System® (QIS®) cyclotron technology, enabling standardized, high-efficiency and cost-effective production of ...

Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...

The pipeline includes promising candidates like Gozellix, Zircaix, and Pixclara, targeting prostate, kidney, and brain cancers, with potential multi-billion dollar market opportunities.

We are pleased to be building upon our successful relationship to bring the accuracy and clinical utility of gallium-based imaging to even more patients across the country with Gozellix®.” ...